We partner with licensed compounding pharmacies
In the meantime, we expect the MedTech sector to hunker down and demonstrate to patients, payors, and investors how their therapies can be used in concert with GLP-1s, and consider how their total addressable markets may increase as new patients become eligible for procedures they may previously not have been candidates for.
During your consultation, well recommend a treatment schedule tailored to your lifestyle and lab results (if applicable)
Participants receiving retatrutide lost an average of 11.5% and as much as 16.8% of their body weight after 40 weeks, far exceeding the placebo groups 2.6% reduction
JAMA Internal Medicine, 182(5), 513
At ShapeIn RX, we offer semaglutide as a part of our comprehensive yet medically supervised non-surgical weight loss program